PE20091656A1 - Compuestos heterociclicos como inhibidores de la cinasa raf - Google Patents

Compuestos heterociclicos como inhibidores de la cinasa raf

Info

Publication number
PE20091656A1
PE20091656A1 PE2009000430A PE2009000430A PE20091656A1 PE 20091656 A1 PE20091656 A1 PE 20091656A1 PE 2009000430 A PE2009000430 A PE 2009000430A PE 2009000430 A PE2009000430 A PE 2009000430A PE 20091656 A1 PE20091656 A1 PE 20091656A1
Authority
PE
Peru
Prior art keywords
amino
metoxy
inhibitors
imidazol
pyrimidin
Prior art date
Application number
PE2009000430A
Other languages
English (en)
Inventor
Zilin Huang
Jeff Jin
Timothy D Machajewski
William R Antonios-Mccrea
Maureen Mckenna
Daniel Poon
Paul A Renhowe
Martin Sendzik
Cynthia M Shafer
Aaron Smith
Yongjin Xu
Qiong Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40734805&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091656(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20091656A1 publication Critical patent/PE20091656A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

SE REFIERE A COMPUESTOS HETEROCICLICOS SUSTITUIDOS DE FORMULA (I) DONDE (a) ES (i) O (ii), DONDE X E Y SON CADA UNO NR4, O U S; R4 ES H O ALQUILO OPCIONALMENTE SUSTITUIDO; R1 Y R2 SON CADA UNO HETEROARILO O HETEROCICLILO OPCIONALMENTE SUSTITUIDOS; R3 ES ALQUILO, ARILO, HETEROARILO, ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS. SON COMPUESTOS PREFERIDOS: N-(2-(4-(5-(6-AMINO-5-METOXI-PIRIDIN-3-IL)-2-(4-FLUORO-FENIL)-1H-IMIDAZOL-4-IL)-PIRIMIDIN-2-IL-AMINO)-ETIL)-2-METOXI-ACETAMIDA, N-(2-(4-(4-(6-AMINO-5-METOXI-PIRIDIN-3-IL)-2-(4-(TRIFLUORO-METIL)-FENIL)-1H-IMIDAZOL-5-IL)-PIRIMIDIN-2-IL-AMINO)-ETIL)-2-METOXI-ACETAMIDA, (S)-N-(1-(4-(4-(6-AMINO-5-METOXI-PIRIDIN-3-IL)-2-(4-FLUORO-FENIL)-1H-IMIDAZOL-5-IL)-PIRIMIDIN-2-IL-AMINO)-PROPAN-2-IL)-2-METOXI-ACETAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA CINASA RAF SIENDO UTILES EN EL TRATAMIENTO DE CARCINOMA DE PULMON, CARCINOMA PANCREATICO, CARCINOMA DE COLON, MELANOMA
PE2009000430A 2008-03-21 2009-03-20 Compuestos heterociclicos como inhibidores de la cinasa raf PE20091656A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3872308P 2008-03-21 2008-03-21
US20845809P 2009-02-24 2009-02-24

Publications (1)

Publication Number Publication Date
PE20091656A1 true PE20091656A1 (es) 2009-11-20

Family

ID=40734805

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000430A PE20091656A1 (es) 2008-03-21 2009-03-20 Compuestos heterociclicos como inhibidores de la cinasa raf

Country Status (26)

Country Link
US (1) US8129394B2 (es)
EP (1) EP2274300A2 (es)
JP (2) JP5384611B2 (es)
KR (2) KR101408517B1 (es)
CN (1) CN102015686B (es)
AR (1) AR071283A1 (es)
AU (1) AU2009227013B2 (es)
BR (1) BRPI0908906A2 (es)
CA (1) CA2718936A1 (es)
CL (1) CL2009000687A1 (es)
CO (1) CO6311078A2 (es)
CR (1) CR11681A (es)
DO (1) DOP2010000280A (es)
EA (1) EA201001456A1 (es)
EC (1) ECSP10010559A (es)
IL (1) IL208063A0 (es)
MA (1) MA32232B1 (es)
MX (1) MX2010010317A (es)
NI (1) NI201000156A (es)
PE (1) PE20091656A1 (es)
SM (1) SMAP201000115A (es)
SV (1) SV2010003673A (es)
TW (1) TW201000457A (es)
UY (1) UY31724A (es)
WO (1) WO2009115572A2 (es)
ZA (1) ZA201006505B (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700433T3 (es) 2005-12-13 2019-02-15 Incyte Holdings Corp Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasas Janus
WO2008050732A1 (fr) * 2006-10-23 2008-05-02 Takeda Pharmaceutical Company Limited Dérivé de l'iminopyridine et son utilisation
HUE029236T2 (en) 2007-06-13 2017-02-28 Incyte Holdings Corp (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US8865732B2 (en) * 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
US8481569B2 (en) * 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
US20110039892A1 (en) * 2008-04-23 2011-02-17 Takeda Pharmaceutical Company Limited Iminopyridine derivative and use thereof
EA019641B1 (ru) * 2008-04-23 2014-05-30 Такеда Фармасьютикал Компани Лимитед Производные иминопиридина и их применение
WO2010135621A1 (en) 2009-05-22 2010-11-25 Incyte Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
AR077975A1 (es) * 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
RU2571930C2 (ru) 2010-02-25 2015-12-27 Дана-Фарбер Кэнсер Инститьют, Инк. Мутации braf, обеспечивающие резистентность к ингибиторам braf
ES2662588T3 (es) 2010-03-10 2018-04-09 Incyte Holdings Corporation Derivados de piperidin-4-IL azetidina como inhibidores de JAK1
CN103002875B (zh) 2010-05-21 2016-05-04 因塞特控股公司 Jak抑制剂的局部用制剂
EP2592130B1 (en) * 2010-07-09 2015-01-21 Mitsubishi Gas Chemical Company, Inc. Photochromic material
US8975265B2 (en) 2010-07-12 2015-03-10 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrimidines and —pyridines
AU2011329734B2 (en) 2010-11-19 2015-05-28 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
US8791112B2 (en) * 2011-03-30 2014-07-29 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US9498471B2 (en) 2011-10-20 2016-11-22 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
AU2012335663B2 (en) 2011-11-11 2015-12-24 Array Biopharma Inc. Method of treating a proliferative disease
PL2782557T3 (pl) 2011-11-23 2019-03-29 Array Biopharma, Inc. Formulacje farmaceutyczne
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CN103159735B (zh) * 2011-12-10 2015-12-09 通化济达医药有限公司 取代的咪唑激酶抑制剂
UY34539A (es) * 2011-12-23 2013-06-28 Millennium Pharm Inc Heteroarilos y usos de los mismos
CN104470515B (zh) 2012-05-03 2016-12-07 圣路易斯药学院 用于增加神经营养肽的组合物和方法
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US20150232452A1 (en) * 2012-09-19 2015-08-20 Ruga Corporation Novel raf kinase inhibitors
EA201590930A1 (ru) 2012-11-15 2015-08-31 Инсайт Корпорейшн Лекарственные формы руксолитиниба с замедленным высвобождением
CN105189509B (zh) 2013-03-06 2017-12-19 因赛特公司 用于制备jak抑制剂的方法及中间体
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
SI3030227T1 (sl) 2013-08-07 2020-08-31 Incyte Corporation Dozirne oblike s podaljšanim sproščanjem za inhibitor JAK1
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CA3000633C (en) 2014-10-14 2023-10-03 The Regents Of The University Of California Use of cdk9 and brd4 inhibitors to inhibit inflammation
KR101665231B1 (ko) * 2015-01-30 2016-10-13 순천향대학교 산학협력단 티오페닐 그룹을 갖는 티아졸계 화합물 및 이를 유효성분으로 포함하는 항진균제
KR102193801B1 (ko) * 2015-02-04 2020-12-22 주식회사 메드팩토 만성 골수성 백혈병 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법
GB201614940D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
GB201614934D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
WO2018098361A1 (en) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 12 (cdk12) and uses thereof
UY37556A (es) 2017-01-10 2018-07-31 Bayer Ag Derivados heterocíclicos como pesticidas
WO2018130443A1 (de) 2017-01-10 2018-07-19 Bayer Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel
EP3579872A1 (en) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
EP3600294A4 (en) * 2017-03-23 2020-08-26 Clavius Pharmaceuticals, LLC TRI-SUBSTITUTED IMIDAZOLES FOR INHIBITION OF TGF-BETA AND TREATMENT METHODS
JP7038994B2 (ja) * 2017-10-16 2022-03-22 国立大学法人金沢大学 炭素繊維強化プラスチックの製造方法、炭素繊維強化プラスチック及びセルロース系樹脂
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
CA3086765A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
MX2020007973A (es) 2018-01-30 2020-12-07 Incyte Corp Procesos para preparar (1-(3-fluoro-2-(trifluorometil)isonicotinil )piperidin-4-ona).
CN113768934A (zh) 2018-03-30 2021-12-10 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
WO2020011141A1 (zh) * 2018-07-12 2020-01-16 深圳市塔吉瑞生物医药有限公司 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020150091A1 (en) 2019-01-15 2020-07-23 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020192302A1 (zh) * 2019-03-27 2020-10-01 广州必贝特医药技术有限公司 含嘧啶的三取代咪唑类化合物及其应用
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
PE20221010A1 (es) 2019-08-14 2022-06-15 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
JP2022551668A (ja) 2019-10-11 2022-12-12 インサイト・コーポレイション Ｃｄｋ２阻害剤としての二環式アミン
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
BR112022026904A2 (pt) 2020-07-02 2023-01-24 Bayer Ag Derivados de heterocicleno como agentes de controle de pragas
US11905272B1 (en) 2023-09-12 2024-02-20 King Faisal University 3-(2-(4-methoxypyridin-3-yl)-4,5-diphenyl-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine as an anti-cancer compound
US11932619B1 (en) 2023-09-13 2024-03-19 King Faisal University 3-(2-(6-Methoxypyridin-3-yl)-4,5-diphenyl-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine as an anticancer compound

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
JPS5613715A (en) * 1979-07-13 1981-02-10 Nec Corp Manufacture of coil
DE3029376A1 (de) * 1980-07-31 1982-03-18 Nepera Chemical Co. Inc., Harriman, N.Y. Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen
US5243517A (en) * 1988-08-03 1993-09-07 Westinghouse Electric Corp. Method and apparatus for physiological evaluation of short films and entertainment materials
JP2722586B2 (ja) * 1989-01-13 1998-03-04 大正製薬株式会社 インドリルイミダゾール誘導体
JP2808460B2 (ja) * 1989-11-16 1998-10-08 大正製薬株式会社 イミダゾール誘導体
US6850252B1 (en) * 1999-10-05 2005-02-01 Steven M. Hoffberg Intelligent electronic appliance system and method
US5436830A (en) * 1993-02-01 1995-07-25 Zaltman; Gerald Metaphor elicitation method and apparatus
US5676148A (en) * 1995-03-31 1997-10-14 Siemens Medical Systems Inc. Method and system for doppler ultrasound audio dealiasing
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
IL123950A (en) * 1995-10-06 2001-04-30 Merck & Co Inc Transformed imidazoles with anti-cancer and cytokine-inhibiting activity and pharmaceutical preparations containing them
US5676138A (en) * 1996-03-15 1997-10-14 Zawilinski; Kenneth Michael Emotional response analyzer system with multimedia display
EP0923579A1 (en) * 1996-08-27 1999-06-23 Novartis AG Herbicidal s-substituted 1,2,4,6-thiatriazines
US6099319A (en) * 1998-02-24 2000-08-08 Zaltman; Gerald Neuroimaging as a marketing tool
US6315569B1 (en) * 1998-02-24 2001-11-13 Gerald Zaltman Metaphor elicitation technique with physiological function monitoring
US6358201B1 (en) * 1999-03-02 2002-03-19 Doc L. Childre Method and apparatus for facilitating physiological coherence and autonomic balance
JP2000302680A (ja) * 1999-04-23 2000-10-31 Takeda Chem Ind Ltd 脳保護剤
EP1233769B1 (en) * 1999-11-22 2007-12-26 SmithKline Beecham plc Imidazole derivatives
JP2003520233A (ja) * 2000-01-18 2003-07-02 バーテックス ファーマシューティカルズ インコーポレイテッド ジャイレースインヒビターおよびそれらの使用
CO5271680A1 (es) * 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
GB0005357D0 (en) * 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
GB0007405D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
WO2001090138A2 (en) * 2000-05-19 2001-11-29 The Nutrasweet Company SYNTHESIS OF N-[N-(3,3-DIMETHYLBUTYL)-L-α-ASPARTYL]-L-PHENYLALANINE 1-METHYL ESTER USING OXAZOLIDINONE DERIVATIVES
US20040053943A1 (en) * 2000-11-20 2004-03-18 Adams Jerry L. Novel compounds
EP1377290B1 (en) * 2001-01-26 2006-10-04 Chugai Seiyaku Kabushiki Kaisha Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
CA2498047C (en) * 2002-09-18 2009-05-19 Pfizer Products Inc. Novel imidazole compounds as transforming growth factor (tgf) inhibitors
CA2545942C (en) * 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
US7678810B2 (en) * 2004-03-05 2010-03-16 Taisho Pharmaceutical Co., Ltd Thiazole derivative
KR100749566B1 (ko) * 2004-04-21 2007-08-16 이화여자대학교 산학협력단 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
US20060106020A1 (en) * 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
PE20060315A1 (es) * 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
US7453002B2 (en) * 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
JP2007246520A (ja) * 2006-02-15 2007-09-27 Takeda Yuichiro Ｒａｇｅ阻害剤

Also Published As

Publication number Publication date
CR11681A (es) 2010-10-29
ECSP10010559A (es) 2010-11-30
WO2009115572A3 (en) 2009-12-03
US20100003246A1 (en) 2010-01-07
CA2718936A1 (en) 2009-09-24
KR20130040258A (ko) 2013-04-23
EP2274300A2 (en) 2011-01-19
CN102015686B (zh) 2014-07-02
CN102015686A (zh) 2011-04-13
JP2014040452A (ja) 2014-03-06
CO6311078A2 (es) 2011-08-22
JP2011515371A (ja) 2011-05-19
NI201000156A (es) 2011-03-15
KR20100136516A (ko) 2010-12-28
WO2009115572A2 (en) 2009-09-24
AR071283A1 (es) 2010-06-09
ZA201006505B (en) 2011-05-25
AU2009227013A1 (en) 2009-09-24
SMAP201000115A (it) 2011-01-19
AU2009227013B2 (en) 2013-01-10
IL208063A0 (en) 2010-12-30
EA201001456A1 (ru) 2011-06-30
SV2010003673A (es) 2011-07-05
KR101408517B1 (ko) 2014-06-17
CL2009000687A1 (es) 2010-03-26
DOP2010000280A (es) 2012-09-15
UY31724A (es) 2009-11-10
MA32232B1 (fr) 2011-04-01
BRPI0908906A2 (pt) 2019-09-24
US8129394B2 (en) 2012-03-06
TW201000457A (en) 2010-01-01
MX2010010317A (es) 2010-10-04
JP5384611B2 (ja) 2014-01-08

Similar Documents

Publication Publication Date Title
PE20091656A1 (es) Compuestos heterociclicos como inhibidores de la cinasa raf
PE20140913A1 (es) Inhibidores de nampt y rock
PE20141375A1 (es) Activadores de glucoquinasa
NZ591449A (en) Picolinamide derivatives as kinase inhibitors
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20140865A1 (es) Inhibidores de la tirosina-quinasa de bruton
PE20090709A1 (es) Compuestos heterociclico de 5 miembros
PE20090717A1 (es) Derivados de quinolina como inhibidores de la pi3 quinasa
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20180177A1 (es) Derivados de 1-(het) arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
PE20110894A1 (es) Derivados de pirimidin indol para el tratamiento de cancer
PE20151274A1 (es) Inhibidores de erk y sus usos
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20120650A1 (es) Acetamidas sustituidas por n-(hetero)-arilo y 2-(hetero)-arilo, como moduladores de la senalizacion de wnt
PE20090610A1 (es) Derivados de pirazol sustituidos
EA201000562A1 (ru) Производные n-(пиразол-3-ил)бензамида в качестве активаторов глюкокиназы
PE20120861A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
PE20121058A1 (es) Compuestos que modulan el receptor de androgenos
PE20140502A1 (es) Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y metodos de tratamiento con las mismas
PE20141004A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20140609A1 (es) Diazacarbazoles y metodos de uso
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20110303A1 (es) Derivados de heteroaril acetamidas como activadores de glucoquinasa
PE20110294A1 (es) Compuestos heterociclicos como inhibidores de enzimas de senal especifica
EA201000561A1 (ru) Производные пиридина, пригодные в качестве активаторов глюкокиназы

Legal Events

Date Code Title Description
FD Application declared void or lapsed